Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $17.2 million.

  • Compass Therapeutics' Gains from Investment Securities rose 2596.7% to $17.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.2 million, marking a year-over-year increase of 2596.7%. This contributed to the annual value of $14.1 million for FY2024, which is 7854.24% up from last year.
  • Compass Therapeutics' Gains from Investment Securities amounted to $17.2 million in Q3 2025, which was up 2596.7% from $18.5 million recorded in Q2 2025.
  • Compass Therapeutics' Gains from Investment Securities' 5-year high stood at $18.5 million during Q1 2025, with a 5-year trough of $96000.0 in Q4 2024.
  • In the last 3 years, Compass Therapeutics' Gains from Investment Securities had a median value of $11.3 million in 2024 and averaged $10.6 million.
  • Over the last 5 years, Compass Therapeutics' Gains from Investment Securities had its largest YoY gain of 7551.2% in 2024, and its largest YoY loss of 3962.26% in 2024.
  • Over the past 3 years, Compass Therapeutics' Gains from Investment Securities (Quarter) stood at $159000.0 in 2023, then tumbled by 39.62% to $96000.0 in 2024, then skyrocketed by 17778.12% to $17.2 million in 2025.
  • Its last three reported values are $17.2 million in Q3 2025, $18.5 million for Q2 2025, and $18.5 million during Q1 2025.